HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer

Overview of attention for article published in JAMA Oncology, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 2 news outlets
twitter: 66 X users

facebook: 3 Facebook pages
googleplus: 1 Google+ user

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 3 news stories from 2 outlets.

HSD3B1 Variant and Response to Nonsteroidal CYP17A1 Inhibition in Castration-Resistant Prostate Cancer

The ASCO Post, 08 Nov 2017

By Matthew Stenger Posted: 11/8/2017 9:59:33 AM Last Updated: 11/8/2017 9:59:33 AM Tweet this page Advertisement In men with…

HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer

The ASCO Post, 02 Nov 2017

By Matthew Stenger Posted: 11/1/2017 10:21:55 AM Last Updated: 11/1/2017 10:21:55 AM Tweet this page Advertisement In patients…

HSD3B1 variant may predict treatment response in advanced prostate cancer

medwireNews, 18 Oct 2017

medwireNews: The HSD3B1 1245C variant allele could be used as a biomarker to predict treatment response in different groups of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.